{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T12:35:28Z","timestamp":1794054928387,"version":"4.8.0"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"5","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"abstract":"<jats:p>Prostate cancer progression is predominantly driven by androgen receptor (AR) signaling, and despite initial benefits of androgen deprivation therapy (ADT), most patients eventually develop lethal castration-resistant disease. Cyclic administration of supraphysiologic androgen (SPA) with ADT paradoxically suppresses tumor growth; however, responses are heterogeneous, and the mechanisms underlying the antitumor effects of SPA remain incompletely understood. In this issue of Cancer Research, Kumar and colleagues demonstrate that SPA induces a distinct metabolic response, characterized by AR-dependent induction of polyamine biosynthesis via ODC1 and AMD1. This metabolic rewiring elevates polyamine synthesis while concurrently depleting the methyl donor S-adenosylmethionine (SAM). Although increased polyamine metabolism by SPA may promote adaptive resistance, genetic or pharmacologic inhibition of ODC1 using difluoromethylornithine (DFMO) enhances SPA-induced growth suppression by disrupting protective polyamine pools and further exacerbating SAM depletion, revealing a metabolic vulnerability in SPA-treated prostate cancer cells. Supporting these findings, a clinical trial combining DFMO with bipolar androgen therapy (BAT) demonstrated reduced circulating polyamines in patients, confirming polyamine pathway suppression in patients with different genomic features. Together, this study uncovers a mechanistic link among androgen signaling, polyamine metabolism, and therapeutic response, providing a rationale for targeting metabolic dependencies to improve SPA efficacy.<\/jats:p>\n                  <jats:p>See related article by Kumar et al., p. 1148<\/jats:p>","DOI":"10.1158\/0008-5472.can-25-4807","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:07:03Z","timestamp":1772438823000},"page":"1095-1097","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Polyamine Metabolism as a Metabolic Vulnerability in Prostate Cancer Treated with Supraphysiological Androgens"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2479-1761","authenticated-orcid":false,"given":"Mohammadreza","family":"Alizadeh-Ghodsi","sequence":"first","affiliation":[{"name":"1Department of Urologic Sciences, The University of British Columbia, Vancouver, Canada."},{"name":"2Vancouver Prostate Centre, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0434-9149","authenticated-orcid":false,"given":"Andrew S.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"3Department of Molecular, Cell and Developmental Biology, University of California, Los Angeles, Los Angeles, California."},{"name":"4Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California."},{"name":"5Eli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, Los Angeles, California."},{"name":"6Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"2026030203065693300_bib1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"2026030203065693300_bib2","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1073\/pnas.93.21.11802","article-title":"Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride","volume":"93","author":"Umekita","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026030203065693300_bib3","doi-asserted-by":"crossref","first-page":"269ra2","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026030203065693300_bib4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.20.02759","article-title":"TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer","volume":"39","author":"Denmeade","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026030203065693300_bib5","first-page":"e240208","article-title":"Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer","volume":"32","author":"Rollin","year":"2025","journal-title":"Endocr Relat Cancer"},{"key":"2026030203065693300_bib6","doi-asserted-by":"crossref","first-page":"113221","DOI":"10.1016\/j.celrep.2023.113221","article-title":"MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer","volume":"42","author":"Crowell","year":"2023","journal-title":"Cell Rep"},{"key":"2026030203065693300_bib7","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1158\/0008-5472.CAN-22-2613","article-title":"Supraphysiological androgens promote the tumor suppressive activity of the androgen receptor through cMYC repression and recruitment of the DREAM complex","volume":"83","author":"Nyquist","year":"2023","journal-title":"Cancer Res"},{"key":"2026030203065693300_bib8","first-page":"1148","article-title":"Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer","volume":"86","author":"Kumar","year":"2026","journal-title":"Cancer Res"},{"key":"2026030203065693300_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clgc.2021.08.001","article-title":"Molecular and clinical characterization of patients with metastatic castration resistant prostate cancer achieving deep responses to bipolar androgen therapy","volume":"20","author":"Markowski","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2026030203065693300_bib10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1158\/2767-9764.CRC-21-0139","article-title":"Potent stimulation of the androgen receptor instigates a viral mimicry response in prostate cancer","volume":"2","author":"Alizadeh-Ghodsi","year":"2022","journal-title":"Cancer Res Commun"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/5\/1095\/3743093\/can-25-4807.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/5\/1095\/3743093\/can-25-4807.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:07:05Z","timestamp":1772438825000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/5\/1095\/774873\/Polyamine-Metabolism-as-a-Metabolic-Vulnerability"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,2]]},"published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-4807","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}